Intravitreal Ranibizumab Injection for the Treatment of Retinopathy of Prematurity

Tariq Aldebasi, a, b Muataz A. Guma a Rabia Bashir a Saif Al Saif c Waleed A. Altwajri b, c Abdulkareem M. Al Bekairy d

a Division of Ophthalmology, Department of Surgery, King Abdul Aziz Medical City, Riyadh, Saudi Arabia; b College of Medicine, King Saud bin Abdulaziz University for Health Sciences, National Guard Health Affairs, Riyadh, Saudi Arabia; c Neonatal Intensive Care Department, King Abdul Aziz Medical City, Riyadh, Saudi Arabia; d College of Pharmacy, King Saud bin Abdulaziz University for Health Sciences, National Guard Health Affairs, Riyadh, Saudi Arabia

Significance of the Study

This study contributes useful information on the treatment of retinopathy of prematurity, a leading cause of childhood blindness in the world. This study provides evidence for the successful use of a single dose of 0.3 mg intravitreal ranibizumab in treating advanced stage III retinopathy.

Keywords

Anti-VEGF · Intravitreal injection · Retinopathy of prematurity · Ranibizumab · Childhood blindness · Vitreoretinal fibrosis

Abstract

Objectives: To evaluate the efficacy of a single injection of 0.3 mg intravitreal ranibizumab for the treatment of retinopathy of prematurity (ROP). Methods: We conducted this retrospective case series study at King Abdul Aziz Medical City, Riyadh, Saudi Arabia. Seventy-four eyes of 37 preterm infants with ROP stage III with plus disease in zone I, posterior zone II, and aggressive posterior ROP received a single injection of 0.3 mg intravitreal ranibizumab. The favorable outcome measure was complete regression of the disease with normal vascularization of the retina of those infants. Results: The gestational age of the 37 included cases was in the range of 23–28 weeks and their body weight at birth was between 510 and 1,235 g except for one case with 2,550 g under oxygen therapy <7 days with severe hypoglycemia. All eyes showed a favorable response in terms of regression of plus disease from the first day after treatment, followed by regression of stage III retinopathy. All patients developed complete vascularization over variable periods of time. Conclusion: One injection of 0.3 mg intravitreal ranibizumab is effective in treating ROP stage III mainly in zones I and II.
Ranibizumab for Prematurity Retinopathy Treatment

Introduction

Retinopathy of prematurity (ROP) is a proliferative vascular disorder of the retina affecting premature infants. It is characterized by aberrant retinal vascularization, vitreoretinal fibrosis, macular dragging, and eventually retinal detachment with grave visual outcome [1]. Several studies have shown that the lower the gestational age and birth weight, the higher the chance of developing ROP [2]. Premature infants with associated neonatal morbidities like respiratory distress syndrome, bronchopulmonary dysplasia, sepsis, intraventricular hemorrhage, poor weight gain, and hyperglycemia are at greatest risk of developing this disease [3]. As the survival of very immature infants has improved with advances in neonatal care, the incidence of ROP is also rising. ROP has become the leading cause of preventable childhood blindness in the world [4]. However, timely diagnosis and treatment can prevent serious visual outcomes.

ROP was first recognized as an important cause of blindness in high-income countries in the 1940s and 50s when survival of very-low-birth-weight babies (<1,500 g or approximately <32 weeks’ gestational age) was improving in association with the widespread use of unrestricted oxygen supplementation. This was termed as the first epidemic of ROP which was caused by oxygen supplementation [5]. Restricting the use of oxygen has reduced the incidence of ROP, but it has increased mortality and the risk of cerebral palsy. Since the 1970s, survival of very-low-gestational-age babies (i.e., <28 weeks) has improved in high-income countries as a result of better neonatal care. This was associated with ROP and is recognized as the second epidemic of ROP. ROP is now an increasingly important cause of preventable blindness in China, Southeast Asia, Latin America, and parts of Eastern Europe [6]. In the United States, of 3.9 million infants born each year, about 14,000 are affected by ROP. Among them, 1,100–1,500 (7.5–10.7%) develop disease severe enough to need treatment, and 400–600 infants (2.8–4.2%) become legally blind from ROP each year [7]. This incidence has risen over the years, as it was reported in 2008 to be only 0.12% [8]. Eighty-six percent of the premature infants born in the UK with birth weight <1,500 g survive, and the incidence of stage III ROP is about 8–10% [9].

Vascular endothelial growth factor (VEGF) plays an important role in the pathogenesis of ROP. This growth factor is expressed from immature avascular retina, and its levels are regulated by relative oxygen saturation of the tissue. Accumulation of VEGF leads to anomalous neovascularization with its subsequent effects [10]. Elevated VEGF levels have been detected in patients with ROP [11]. Thus, one approach to treating ROP is aimed at destroying VEGF-producing cells. Laser therapy has largely replaced cryotherapy over the past decades. Both therapies destroy the peripheral retina leading to loss of peripheral vision with high risk of tunnel visual field [12].

More recently, intravitreal injection of anti-VEGF agents, especially bevacizumab, has emerged as an alternative treatment in an effort to salvage peripheral vision. Anti-VEGF therapy is reported to allow normal vascularization of peripheral retina [13]. The better refractive outcomes and the avoidance of the risks of general anesthesia are considered significant advantages of anti-VEGF treatment [13, 14]. Ranibizumab has been introduced as an alternative to bevacizumab with a number of advantages including lack of penetration of the retina, short half-life, and accordingly much less systemic toxicity potential, and higher general safety profile [15].

Among 9,500 babies born in 2016 in King Abdulaziz Medical City (KAMC), Riyadh, Saudi Arabia, 940 were preterm, comprising almost 10%. Among them, 833 were screened for ROP, and 16 of them (1.7%) were diagnosed with advanced ROP. This means that almost 2% of all preterm babies with ROP might need treatment every year. This high incidence of ROP is mainly due to the development in neonatal healthcare.

This study was aimed at evaluating the efficiency of using 0.3 mg ranibizumab, an off-label treatment, via intravitreal injection in 74 eyes of 37 preterm infants followed up from July 2012 to December 2016.

Materials and Methods

This case series study was conducted in the Neonatal Intensive Care Unit and Intermediate Care Unit at KAMC, Riyadh, Saudi Arabia. The study is a joint effort of the Division of Ophthalmology, in collaboration with the Neonatology Department (KAMC), and the College of Pharmacy at King Saud Bin Abdulaziz University for Health Sciences.

This study was approved by the Institutional Review Board of King Abdullah International Medical Research Center, and both verbal and written informed consents were obtained from the parents of all patients. Detailed information on single-dose ranibizumab was provided to the parents. The pros and cons of the old approaches of treatment using cryotherapy and laser were also explained to the parents. The advantages and risks associated with this intravitreal anti-VEGF (ranibizumab) were also explained to all parents.

The study population included all preterm infants admitted to the Neonatal Intensive Care Unit and Intermediate Care Unit from July 2012 to December 2016 with a gestational age ≤31 weeks at birth and a birth weight ≤1,500 g. Infants with a gestational age ≤31 weeks at birth and a birth weight ≤1,500 g.
A total of 74 eyes of 37 preterm babies underwent intravitreal ranibizumab injection for ROP type 1:

- 32 preterm babies were with plus disease stage III in zone II in both eyes (5 babies, 10 eyes were with the disease in posterior zone II).
- 2 preterm babies were with aggressive posterior ROP in both eyes.
- 3 preterm babies were with plus disease stage III in zone I.

Intravitreal injections were performed under topical anesthesia after installation of povidone iodine. The lid specula were inserted, and injections were performed at 1.5 mm from the limbus with a 30-gauge needle. The dose used was 0.3 mg/0.03 mL ranibizumab. Intraocular pressure and fundoscopic examination were performed after all injections. Infants were followed on day 1, and then after 1 week. All patients were followed weekly till the retina was completely vascularized. After that, they were evaluated every 3–4 months till the end of the study period.

Results

All eyes showed substantial response to intravitreal ranibizumab injection since day 1. Regression of plus disease was observed from the following day which was followed by the regression of stage III. Figure 1 depicts a fundus photograph of one eye indicating the regression of ROP threshold disease 1 week after the treatment (panel d), while panels a–c demonstrate the rapid progression in only 2 weeks from ROP stage I, stage II, and stage III, respectively.

A total of 37 infants were included in the study. Mean gestational age ± SD was 25.0 ± 1.4 weeks, median (range) was 25 weeks (23–28), with 51% males. Mean birth weight ± SD was 770.3 ± 335.5 g, median (range) was 720 g (510–2550). Mean post-conceptual age at injection ± SD was 770.3 ± 335.5 g, median (range) was 720 g (510–2550). Mean post-conceptual age at injection ± SD was 770.3 ± 335.5 g, median (range) was 720 g (510–2550). Mean post-conceptual age at injection ± SD was 770.3 ± 335.5 g, median (range) was 720 g (510–2550).
Ranibizumab for Prematurity Retinopathy

Treatment

Table 2. Characteristics of the treated cases according to gestational age (GA in weeks), body weight at birth (BW in g), the stage and zone of the retinopathy of prematurity (ROP), and time of initial and complete regression

| Case | GA | Gender | BW  | Treatment, mg | Stage at injection | Reg+, h | Reg ROP, weeks | Complication | Recurrence |
|------|----|--------|-----|---------------|--------------------|--------|---------------|--------------|------------|
| 1    | 23 | F      | 660 | 0.3           | SIII/ZII+          | 24     | 6             | No           |            |
| 2    | 26 | M      | 2,550| 0.3           | SIII/ZII+          | 48     | 8             | Subconj. Hg. | No         |
| 3    | 24 | F      | 565 | 0.3           | SIII/ZII+          | 24     | 8             | No           |            |
| 4    | 28 | M      | 670 | 0.3           | SIII/ZI+           | 24     | 7             | No           |            |
| 5    | 28 | F      | 1,235| 0.3           | SIII/ZII+          | 48     | 6             | Subconj. Hg. | No         |
| 6    | 24 | M      | 740 | 0.3           | SIII/ZII+          | 24     | 9             | No           |            |
| 7    | 27 | F      | 750 | 0.3           | SIII/ZII+          | 24     | 6             | No           |            |
| 8    | 24 | M      | 675 | 0.3           | SIII/ZII+          | 48     | 8             | No           |            |
| 9    | 24 | F      | 965 | 0.3           | SIII/ZII+          | 24     | 8             | Subconj. Hg. | No         |
| 10   | 24 | M      | 800 | 0.3           | SIII/ZII+          | 24     | 9             | No           |            |
| 11   | 24 | F      | 560 | 0.3           | SIII/ZII+          | 48     | 10            | No           |            |
| 12   | 27 | F      | 595 | 0.3           | SIII/ZII+          | 24     | 7             | No           |            |
| 13   | 24 | F      | 730 | 0.3           | SIII/ZII+          | 24     | 5             | No           |            |
| 14   | 26 | F      | 820 | 0.3           | SIII/ZII+          | 24     | 7             | No           |            |
| 15   | 28 | M      | 935 | 0.3           | SIII/ZI+           | 24     | 8             | Subconj. Hg. | No         |
| 16   | 25 | M      | 880 | 0.3           | SIII/ZII+          | 48     | 7             | No           |            |
| 17   | 24 | M      | 550 | 0.3           | SIII/ZII+          | 24     | 4             | No           |            |
| 18   | 25 | F      | 725 | 0.3           | SIII/ZII+          | 24     | 6             | No           |            |
| 19   | 24 | M      | 560 | 0.3           | SIII/ZII+          | 24     | 7             | No           |            |
| 20   | 27 | F      | 820 | 0.3           | SIII/ZII+          | 24     | 8             | No           |            |
| 21   | 24 | M      | 555 | 0.3           | SIII/ZII+          | 24     | 8             | No           |            |
| 22   | 23 | F      | 525 | 0.3           | SIII/ZII+          | 24     | 4             | No           |            |
| 23   | 25 | M      | 795 | 0.3           | SIII/ZII+          | 24     | 7             | No           |            |
| 24   | 27 | M      | 900 | 0.3           | SIII/ZII+          | 24     | 6             | No           |            |
| 25   | 25 | F      | 810 | 0.3           | SIII/ZI+           | 48     | 6             | No           |            |
| 26   | 25 | M      | 900 | 0.3           | SIII/ZII+          | 24     | 5             | No           |            |
| 27   | 26 | F      | 750 | 0.3           | SIII/ZII+          | 24     | 9             | No           |            |
| 28   | 25 | M      | 700 | 0.3           | SIII/ZII+          | 24     | 7             | No           |            |
| 29   | 25 | M      | 710 | 0.3           | SIII/ZII+          | 24     | 8             | No           |            |
| 30   | 23 | M      | 650 | 0.3           | SIII/ZII+          | 24     | 10            | No           |            |
| 31   | 24 | M      | 600 | 0.3           | SIII/ZII+          | 24     | 6             | No           |            |
| 32   | 24 | M      | 750 | 0.3           | SIII/ZII+          | 24     | 7             | No           |            |
| 33   | 24 | F      | 510 | 0.3           | AP-ROP, ZI         | 48     | 7             | No           |            |
| 34   | 25 | F      | 720 | 0.3           | SIII/ZI+           | 24     | 7             | No           |            |
| 35   | 23 | F      | 530 | 0.3           | AP-ROP, ZI         | 48     | 9             | No           |            |
| 36   | 25 | M      | 770 | 0.3           | SIII/ZII+          | 24     | 8             | No           |            |
| 37   | 25 | F      | 720 | 0.3           | SIII/ZII+          | 24     | 10            | No           |            |

Reg+, initial regression of plus disease; Reg ROP, advancement of normal retinal vasculature; Subconj. Hg., subconjunctival hemorrhage.

Gestational age, birth weight, or conceptual age at injection were not related to regression (+) within 24 h.

All 37 patients had regression of ROP within 10 weeks of injection, 21 patients (56.8%) had regression of ROP within 7 weeks of injection. Gestational age, birth weight, gender, or conceptual age at injection were also not related to earlier regression of ROP (within 7 weeks).

All of the cases had completely regressed tortuosity and dilatation of retinal blood vessels by the end of the
first week with a decreasing volume of ridge. There was a total regression of stage III after 4–8 weeks. The vessels started growing over the ridge towards the periphery, and this was complete in most infants in 3 months. The close follow-up period was 12 months in 17 infants and 6 months in the rest of the treatment group.

With regard to adverse effects, only 4 of our patients developed subconjunctival hemorrhage in one of their eyes. Despite that almost all premature babies had some degree of intraventricular hemorrhage prior to the intravitreal injection, none of them had an increase in the degree of intraventricular hemorrhage after the injection. None of the treated eyes had a post-injection elevation of intraocular pressure that required intervention. Regarding neurodevelopmental issues, 5 of our patients are still being followed in the neurosurgery clinic and the rehabilitation department, as they underwent ventriculo-peritoneal shunt surgeries for hemorrhagic hydrocephalus. We believe that this presentation is not associated with the treatment, and it is a known consequence of prematurity. One 4-year-old is scheduled for squint surgery, and the other four are regular patients in the optometry clinic being followed up for amblyopia therapy for anisometropia. No other systemic side effects were noted both during the treatment and in the follow-up period.

Discussion

Our results are consistent with the studies of Menke et al. [16] and Castellanos et al. [17] who also reported complete resolution of stage III ROP with plus disease in zone II with no recurrence during the 6-month follow-up period. They used the same dose and the mean gestational age as well; the mean postmenstrual age at injection was also not statistically different from that of our patients. However, these two studies had small sample sizes of 6 eyes each. Chen et al. [18] compared the efficacy of intravitreal ranibizumab with bevacizumab in two groups of premature children with ROP. The authors concluded similar efficacy of both drugs in terms of regression of the disease. Another retrospective study conducted by Arámbulo et al. [19] in Brazil compared the results obtained with intravitreal ranibizumab treatment alone and combined treatment with ranibizumab and laser photocoagulation. 87.5% of the cases showed favorable results in terms of regression of neovascularization with ranibizumab (0.25 mg) in 16 eyes, while 12.5% of the patients had unfavorable results in the form of disease progression to stage 4 and 5. In the group treated with ranibizumab and laser, favorable results were only achieved in 70.7% of the eyes.

In our study, we had 3 extremely premature infants with a very low gestational age of 23 weeks and birth
weight ranging between 530 and 660 g. They responded very well to the treatment. This is in agreement with a case of extremely low birth weight (480 g with a gestational age of 23 weeks) with Rush disease reported by Lin et al. [20]. The infant was first treated with combined intravitreal bevacizumab and laser therapy, and no progress was achieved. After a single injection of intravitreal ranibizumab, complete resolution of the disease was achieved with no recurrence during a follow-up period of 2 years.

It is worth mentioning that fluorescein angiography is a more sensitive tool for the detection of peripheral vascular growth compared to fundoscopic examination, the clinical tool used in our study. However, diagnosis of recurrence was confirmed in many studies based on clinical examination alone [21–25].

Our results are consistent with the reports mentioned above regarding the initial response and recurrence; however, we cannot directly compare the results as there is a difference in sample size as well as the anti-VEGF agent and dose used. The dose of ranibizumab used in our patients was 0.3 mg, whereas in all of the mentioned reports (except for the one by Menke et al. [16]) the dose used was 0.2–0.25 mg. Despite the relatively smaller dose, the above-mentioned reports have shown almost 100% positive outcomes in terms of initial regression.

Several reports indicated late recurrence of ROP after different anti-VEGF treatment [26–28]. A randomized clinical trial concluded that single-dose anti-VEGF monotherapy is not recommended for ROP in zone II due to a high probability of early recurrence [29]. They reported that 26 eyes out of 50 (52%) had a recurrence of ROP within a maximum follow-up period of 79 weeks after intravitreal injection of ranibizumab. A similar observation was reported by Mintz-Hittner et al. [13] for bevacizumab monotherapy. Other studies reported a higher incidence of recurrence in patients treated with intravitreal ranibizumab compared to bevacizumab-treated cases [21–25]. The ranibizumab dose used in those studies was between 0.2 and 0.25 mg, while in our study, a dose of 0.3 mg was used. This may explain the absence of recurrence in our study. The lower postconceptional age at the time of treatment, the zone, and extent of disease in the affected eye are possible determinant factors for recurrence. Some reports showed a reduced risk of recurrence with ROP in zone I after treatment with anti-VEGF and bevacizumab [13, 30].

This study showed lower adverse effects compared to many studies including the study of Menke et al. [16] who reported that paracentesis had to be performed in 3 out of the 6 eyes included in their study. Other studies demonstrated a higher incidence of neurodevelopmental disabilities, starting from 18 months of corrected gestational age, in patients treated with bevacizumab [31, 32].

**Conclusion**

We conclude that the use of a single intravitreal injection of 0.3 mg ranibizumab is effective in treating advanced ROP stage III mainly in zone II and also in zone I. The treatment led to complete regression of plus disease within 24–48 h. The retinal vessels progressed anteriorly, and complete retinal vascularization was achieved within 4–10 weeks of treatment. Although treatment with intravitreal ranibizumab is generally well tolerated, long-term ocular and systemic effects need to be investigated with further prospective trials using larger sample sizes and longer follow-up periods. More studies are needed to optimize the dose of ranibizumab and other anti-VEGF agents.

**Statement of Ethics**

This study was approved by the Institutional Review Board of King Abdullah International Medical Research Center, and both verbal and written informed consents were obtained from the parents of all patients.

**Disclosure Statement**

All authors have no conflict of interest to disclose.

**References**

1. Hellström A, Smith LE, Dammann O. Retinopathy of prematurity. *Lancet*. 2013 Oct; 382(9902):1445–57.
2. Liu L, Tian T, Zheng CX, Ileana V, Ioana A, Tatiana C, et al. Risk factors and laser therapy for retinopathy of prematurity in neonatal intensive care unit. *World J Pediatr*. 2009 Nov; 5(4):304–7.
3. Lee J, Dammann O. Perinatal infection, inflammation, and retinopathy of prematurity. *Semin Fetal Neonatal Med*. 2012 Feb; 17(1):26–9.
4. Shah PK, Prabh V, Karandikar SS, Ranjan R, Narendran V, Kalpana N. Retinopathy of prematurity: Past, present and future. *World J Clin Pediatr*. 2016 Feb;5(1):35–46.
5. Cross KW. Cost of preventing retrolental fibroplasia? *Lancet*. 1973 Oct;2(7835):954–6.
12 Early Treatment For Retinopathy Of Prematurity. N Engl J Med. 2011 Feb;364(7):675–80.
23 Baumal CR, Goldberg RA, Fein JG. Primary intravitreal ranibizumab for high-risk retinopathy of prematurity. *Ophthalmic Surg Lasers Imaging Retina*. 2015 Apr;46(4):432–8.
26 Snyder LL, Garcia-Gonzalez JM, Shapiro MJ, Blair MP. Very late reactivation of retinopathy of prematurity after monotherapy with intravitreal bevacizumab. *Ophthalmic Surg Lasers Imaging Retina*. 2016 Mar;47(3):280–3.
27 Hu J, Blair MP, Shapiro MJ, Lichtenstein SJ, Galasso JM, Kapur R, Hu J, Blair MP, Shapiro MJ, Lichtenstein SJ, Galasso JM, Kapur R. Reactivation of retinopathy of prematurity after bevacizumab injection. *Arch Ophthalmol*. 2012;130(8):1000–6.
28 Hajrasouliha AR, Garcia-Gonzales JM, Shapiro MJ, Yoon H, Blair MP. Reactivation of Retinopathy of Prematurity Three Years After Treatment With Bevacizumab. *Ophthalmic Surg Lasers Imaging Retina*. 2017 Mar;48(3):255–9.
29 Zhang G, Yang M, Zeng J, Vakros G, Su K, Chen M, et al. Comparison of intravitreal injection of ranibizumab versus laser therapy for zone II treatment-requiring retinopathy of prematurity. *Retina*. 2017 Apr;37(4):710–7.
30 Reynolds JD. Bevacizumab for retinopathy of prematurity. *N Engl J Med*. 2011 Feb;364(7):677–8.
31 Morin J, Luu TM, Superstein R, Ospina LH, Lefebvre F, Simard MN, et al.; Canadian Neonatal Network and the Canadian Neonatal Follow-Up Network Investigators. Neurodevelopmental outcomes following bevacizumab injections for retinopathy of prematurity. *Pediatrics*. 2016 Apr;137(4):e20153218.
32 Araz-Ersan B, Kir N, Tuncer S, Aydinoglu-Candan O, Yildiz-Inec D, Akdogan B, et al. Preliminary anatomical and neurodevelopmental outcomes of intravitreal bevacizumab as adjunctive treatment for retinopathy of prematurity. *Curr Eye Res*. 2015 May;40(6):585–91.